Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.47 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31189120 | 0.90 | PPM1B (0.45) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL31181970 | 0.90 | PPM1B (0.45) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL29939086 | 0.79 | PPM1B (0.43) | PPM1BPTPN1PPP1CCTSHR | |
| SCHEMBL11608437 | 0.78 | PPM1B (0.54) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL16391345 | 0.76 | — | — | |
| SCHEMBL4914627 | 0.75 | — | — | |
| SCHEMBL19565576 | 0.75 | — | — | |
| SCHEMBL19565577 | 0.75 | — | — | |
| SCHEMBL15712143 | 0.74 | PPM1B (0.53) | PPM1BPTPN1PPP1CCMAPTALDH1A1 | |
| SCHEMBL34468392 | 0.74 | PPM1B (0.46) | PPM1BPTPN1PPP1CCMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111196804-B | TGF-beta R1 inhibitors and uses thereof | 南京圣和药业股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2611295-B1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | PURDUE RESEARCH FOUNDATION (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9487541-B2 | Fused tricyclic ether carbamates and their use | PURDUE RESEARCH FOUNDATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-9487541-B2 | Fused tricyclic ether carbamates and their use | PURDUE RESEARCH FOUNDATION (US) | 2016-11-08 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-22 | — | — | US | disclosed |
| WO-2015005901-A1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-15 | — | — | WO | disclosed |
| US-20140179754-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179754-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2014-06-26 | — | — | US | disclosed |
| US-8563597-B2 | Fused tricyclic ether carbamates and their use | PURDUE RESEARCH FOUNDATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-8563597-B2 | Fused tricyclic ether carbamates and their use | PURDUE RESEARCH FOUNDATION (US) | 2013-10-22 | — | — | US | disclosed |
| US-20130158094-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | PURDUE RESEARCH FOUNDATION (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158094-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | PURDUE RESEARCH FOUNDATION (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2012031237-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | PURDUE RESEARCH FOUNDATION (US) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158094-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | CTSE, DNPEP, CTSS | PPM1B 3698/4885PTPN1 4460/4885PPP1CC 3866/4885 |
| US-20150023913-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, EIF2AK2 | PPM1B 145/4885PTPN1 344/4885PPP1CC 290/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | PPM1B 156/4885PTPN1 482/4885PPP1CC 552/4885 |
| US-20140179754-A1 | FUSED TRICYCLIC ETHER CARBAMATES AND THEIR USE | CTSE, DNPEP, CTSS | PPM1B 3698/4885PTPN1 4460/4885PPP1CC 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.